Details for Patent: 12,013,403
Which drugs does patent 12,013,403 protect, and when does it expire?
Patent 12,013,403 protects SPINRAZA and is included in one NDA.
This patent has five patent family members in four countries.
Summary for Patent: 12,013,403
| Title: | Compositions and methods for detection of SMN protein in a subject and treatment of a subject |
| Abstract: | Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid. |
| Inventor(s): | Frank Rigo, Katherine M. Bishop |
| Assignee: | Biogen MA Inc |
| Application Number: | US17/365,365 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,013,403 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Recent additions to Drugs Protected by US Patent 12,013,403
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Req. | Patent Expiration | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Dec 23, 2016 | RX | Yes | 12,013,403 | ⤷ Start Trial | U-1941 | TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY | |||
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Mar 27, 2026 | RX | Yes | 12,013,403 | ⤷ Start Trial | U-1941 | TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY | |||
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Dec 23, 2016 | RX | Yes | 12,013,403 | ⤷ Start Trial | U-1942 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA | |||
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION | 209531 | Mar 27, 2026 | RX | Yes | 12,013,403 | ⤷ Start Trial | U-1942 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Req. | >Patent Expiration | >Usecode | >Patented / Exclusive Use |
Drugs Protected by US Patent 12,013,403
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | 12,013,403 | ⤷ Start Trial | TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY | ⤷ Start Trial | ||||
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | 12,013,403 | ⤷ Start Trial | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA | ⤷ Start Trial | ||||
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | 12,013,403 | ⤷ Start Trial | TREATMENT OF SPINAL MUSCULAR ATROPHY | ⤷ Start Trial | ||||
| Biogen | SPINRAZA | nusinersen sodium | SOLUTION;INTRATHECAL | 209531-001 | Dec 23, 2016 | RX | Yes | Yes | 12,013,403 | ⤷ Start Trial | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,013,403
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Brazil | 112017004056 | ⤷ Start Trial | |||
| Chile | 2017000594 | ⤷ Start Trial | |||
| Chile | 2019000447 | ⤷ Start Trial | |||
| Colombia | 2017002400 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
